Do probiotics help bacterial vaginosis?

What the evidence shows

Comparisons with antibiotics did not show a clear probiotic advantage, while some pooled analyses modestly favored adding probiotics to antibiotics over antibiotics alone. Regimens varied in strain, route, and amount, and no standardized strain or dose was established.^{[1], [2]}

The evidence is specific to women with bacterial vaginosis

The supporting randomized trials enrolled women with bacterial vaginosis and evaluated condition-specific clearance outcomes.^{[1], [2]}

These findings should not be generalized into a broad claim that a generic women's probiotic addresses other vaginal or reproductive outcomes.^{[1], [2]}

Pooled trials reported higher clearance than placebo

In meta-analyses of randomized controlled trials, Lactobacillus-based probiotics were associated with a higher bacterial-vaginosis clearance rate than placebo.^{[1], [2]}

The pooled estimate combines different strains, routes, and amounts, so it does not predict the result of a specific retail product.^{[1], [2]}

The evidence did not show a clear advantage over antibiotics

When probiotics were compared directly with antibiotics, the pooled evidence did not show a clear difference.^{[1], [2]}

Some analyses modestly favored probiotics added to antibiotics over antibiotics alone, but an add-on result does not establish that probiotics can replace established therapy.^{[1], [2]}

Both oral and vaginal regimens were studied

The randomized-trial literature included Lactobacillus-based products administered by mouth and products administered vaginally.^{[1], [2]}

Because route and strain varied across trials, evidence for one preparation should not be transferred automatically to another route, strain, or product.^{[1], [2]}

No standardized strain or amount was established

The pooled studies differed in Lactobacillus strain or mixture, route, and dose.^{[1], [2]}

The reviews did not identify one standardized strain or dose that can be treated as a universal bacterial-vaginosis regimen.^{[1], [2]}

Short-term adverse-event rates were similar to control

Across pooled randomized trials, the studied probiotic regimens were not associated with extra adverse events compared with control groups.^[2]

This finding reflects short-duration trials using the studied products. It does not establish long-term safety or suitability for every person or medical context.^[2]

Heterogeneity and small trials keep certainty low

The pooled evidence showed high statistical heterogeneity, and many of the individual trials were small.^{[1], [2]}

Review authors characterized the overall evidence as weak and called for larger, more uniform trials before firmer conclusions or standardized recommendations are made.^{[1], [2]}

Questions covered by the supporting research

These related questions are addressed in the cited evidence summaries and linked pages.

• Did probiotics outperform placebo?
• Did probiotics outperform antibiotics?
• Were oral and vaginal products both studied?
• Did the reviews identify one strain or dose?

Read the supporting evidence summaries

The linked research pages provide study populations, formulations, doses, outcomes, and limitations in greater detail.

• Probiotics for Women →
• Probiotics: What Qualifies and Why Strain Matters →

Related questions

• Why does the probiotic strain matter?
• What does CFU mean in probiotics?
• How do you choose a probiotic supplement?
• What probiotic benefits are supported beyond digestion?